Biora Therapeutics, Inc. Common Stock
BIOR
BIOR was delisted on the 10th of December, 2024.
29 hedge funds and large institutions have $16.1M invested in Biora Therapeutics, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 3 closing their positions.
1,890% more call options, than puts
Call options by funds: $1.75M | Put options by funds: $88K
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
21% more funds holding
Funds holding: 24 → 29 (+5)
38% less capital invested
Capital invested by funds: $25.9M → $16.1M (-$9.83M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$372K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$82.4K |
| 3 |
VF
Virtu Financial
New York
|
+$32K |
| 4 |
EGM
Engineers Gate Manager
New York
|
+$24.5K |
| 5 |
Millennium Management
New York
|
+$20.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$817K |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$7.62K |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$3.89K |
| 4 |
LPL Financial
San Diego,
California
|
-$1.31K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1.17K |
BIOR Hedge Fund Activity: Q4 2023 in Review
29 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Biora Therapeutics, Inc. Common Stock (BIOR) for Q4 2023, worth a combined $16.1M — down 38% from $25.9M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new BIOR positions and 3 closed out — a net gain of 5 holders — while 8 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $372K. The largest seller was Sabby Management, exiting entirely with an estimated $817K sold.
- 29 institutional investors held Biora Therapeutics, Inc. Common Stock (BIOR) as of Q4 2023, up from 24 in Q3 2023.
- Funds reported $16.1M of Biora Therapeutics, Inc. Common Stock stock for Q4 2023, down 38% quarter-over-quarter.
- 8 funds opened new Biora Therapeutics, Inc. Common Stock positions in Q4 2023 and 3 closed out, a net change of +5 holders.
- The largest Biora Therapeutics, Inc. Common Stock buyer in Q4 2023 was Vanguard Group, an estimated $372K added.
- The largest Biora Therapeutics, Inc. Common Stock seller in Q4 2023 was Sabby Management, an estimated $817K sold.
Based on aggregated 13F filings for Q4 2023.